Vimarsana
Biggest News Aggregation in the World

Page 6 - Cell Avidity News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cell Avidity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cell Avidity Today - Breaking & Trending Today

LUMICKS Further Strengthens Leadership Team, Appoints Joshua Young as Vice President of Investor Relations, Communications and Strategy - Vimarsana News

LUMICKS Further Strengthens Leadership Team, Appoints Joshua Young as Vice President of Investor Relations, Communications and Strategy

/PRNewswire/ -- LUMICKS, a next generation life science tools company, today announced it has appointed Joshua Young to lead the company's Investor Relations,...

LUMICKS Further Strengthens Leadership Team, Appoints Joshua Young as Vice President of Investor Relations, Communications and Strategy - Vimarsana News

LUMICKS Further Strengthens Leadership Team, Appoints Joshua Young as Vice President of Investor Relations, Communications and Strategy

AMSTERDAM, Oct. 27, 2021 /PRNewswire/ -- LUMICKS, a next generation life science tools company, today announced it has appointed Joshua Young to lead the company's Investor Relations, Communications

Regensburg Center for Interventional Immunology adopts LUMICKS' z-Movi® Cell Avidity Analyzer - Vimarsana News

Regensburg Center for Interventional Immunology adopts LUMICKS' z-Movi® Cell Avidity Analyzer

/PRNewswire/ -- In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in...

Regensburg Center for Interventional Immunology adopts LUMICKS' z-Movi® Cell Avidity Analyzer - Vimarsana News

Regensburg Center for Interventional Immunology adopts LUMICKS' z-Movi® Cell Avidity Analyzer

Regensburg Center for Interventional Immunology adopts LUMICKS’ z-Movi® Cell Avidity Analyzer Amsterdam, the Netherlands – May 27, 2021 – In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in Germany has purchased LUMICKS’ z-Movi® Cell Avidity Analyzer. The placement highlights the promise of measuring cell avidity between immune cells and their tumor targets to improve the selection of chimeric antigen receptors (CARs) and accelerate the development of new CAR-T therapies. The new instrument h...

Lumicks Raises $93M in Series D Financing - Vimarsana News

Lumicks Raises $93M in Series D Financing

Lumicks, an Amsterdam, The Netherlands-based life science tools company that develops innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, closed a $93m Series D funding. The round was led by new investors Farallon Capital Management and Lauxera Capital Partners, with participation from Softbank Vision 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Pura Vida Investments, and Irving Investors, as well as existing investor Gilde Healthcare and select members of the management team. The company intends to use the funds to accelerate...